214 related articles for article (PubMed ID: 25682035)
41. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
[TBL] [Abstract][Full Text] [Related]
42. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
[TBL] [Abstract][Full Text] [Related]
43. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
[TBL] [Abstract][Full Text] [Related]
44. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
[TBL] [Abstract][Full Text] [Related]
45. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.
Qian YW; Schmidt RJ; Zhang Y; Chu S; Lin A; Wang H; Wang X; Beyer TP; Bensch WR; Li W; Ehsani ME; Lu D; Konrad RJ; Eacho PI; Moller DE; Karathanasis SK; Cao G
J Lipid Res; 2007 Jul; 48(7):1488-98. PubMed ID: 17449864
[TBL] [Abstract][Full Text] [Related]
46. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
[TBL] [Abstract][Full Text] [Related]
47. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Schiele F; Park J; Redemann N; Luippold G; Nar H
J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
[TBL] [Abstract][Full Text] [Related]
48. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Maxwell KN; Fisher EA; Breslow JL
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
[TBL] [Abstract][Full Text] [Related]
49. PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.
Saavedra YG; Zhang J; Seidah NG
PLoS One; 2013; 8(8):e72113. PubMed ID: 23951290
[TBL] [Abstract][Full Text] [Related]
50. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
Dong B; Singh AB; Fung C; Kan K; Liu J
Atherosclerosis; 2014 Aug; 235(2):449-62. PubMed ID: 24950000
[TBL] [Abstract][Full Text] [Related]
51. Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.
Venugopal J; Wang J; Guo C; Lu H; Chen YE; Eitzman DT
Sci Rep; 2020 Oct; 10(1):16514. PubMed ID: 33020528
[TBL] [Abstract][Full Text] [Related]
52. Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model.
Dandan M; Han J; Mann S; Kim R; Mohammed H; Nyangau E; Hellerstein M
Arterioscler Thromb Vasc Biol; 2021 Dec; 41(12):2866-2876. PubMed ID: 34615375
[TBL] [Abstract][Full Text] [Related]
53. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
Fisher TS; Lo Surdo P; Pandit S; Mattu M; Santoro JC; Wisniewski D; Cummings RT; Calzetta A; Cubbon RM; Fischer PA; Tarachandani A; De Francesco R; Wright SD; Sparrow CP; Carfi A; Sitlani A
J Biol Chem; 2007 Jul; 282(28):20502-12. PubMed ID: 17493938
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
55. PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.
Roubtsova A; Chamberland A; Marcinkiewicz J; Essalmani R; Fazel A; Bergeron JJ; Seidah NG; Prat A
J Lipid Res; 2015 Nov; 56(11):2133-42. PubMed ID: 26323289
[TBL] [Abstract][Full Text] [Related]
56. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
57. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
Chan JC; Piper DE; Cao Q; Liu D; King C; Wang W; Tang J; Liu Q; Higbee J; Xia Z; Di Y; Shetterly S; Arimura Z; Salomonis H; Romanow WG; Thibault ST; Zhang R; Cao P; Yang XP; Yu T; Lu M; Retter MW; Kwon G; Henne K; Pan O; Tsai MM; Fuchslocher B; Yang E; Zhou L; Lee KJ; Daris M; Sheng J; Wang Y; Shen WD; Yeh WC; Emery M; Walker NP; Shan B; Schwarz M; Jackson SM
Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9820-5. PubMed ID: 19443683
[TBL] [Abstract][Full Text] [Related]
58. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
[TBL] [Abstract][Full Text] [Related]
59. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
Lagace TA; Curtis DE; Garuti R; McNutt MC; Park SW; Prather HB; Anderson NN; Ho YK; Hammer RE; Horton JD
J Clin Invest; 2006 Nov; 116(11):2995-3005. PubMed ID: 17080197
[TBL] [Abstract][Full Text] [Related]
60. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
Le May C; Berger JM; Lespine A; Pillot B; Prieur X; Letessier E; Hussain MM; Collet X; Cariou B; Costet P
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1484-93. PubMed ID: 23559630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]